Our top pick for
Building a portfolio
Kodiak Sciences Inc is a biotechnology business based in the US. Kodiak Sciences shares (KOD) are listed on the NASDAQ and all prices are listed in US Dollars. Kodiak Sciences employs 72 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$42.97 - $171.21|
|50-day moving average||$119.69|
|200-day moving average||$121.45|
|Wall St. target price||$138.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-11.92%|
|Return on equity TTM||-22.07%|
|Market capitalisation||$5.9 billion|
TTM: trailing 12 months
There are currently 3.3 million Kodiak Sciences shares held short by investors – that's known as Kodiak Sciences's "short interest". This figure is 0.2% up from 3.3 million last month.
There are a few different ways that this level of interest in shorting Kodiak Sciences shares can be evaluated.
Kodiak Sciences's "short interest ratio" (SIR) is the quantity of Kodiak Sciences shares currently shorted divided by the average quantity of Kodiak Sciences shares traded daily (recently around 328788.35143139). Kodiak Sciences's SIR currently stands at 10.13. In other words for every 100,000 Kodiak Sciences shares traded daily on the market, roughly 10130 shares are currently held short.
However Kodiak Sciences's short interest can also be evaluated against the total number of Kodiak Sciences shares, or, against the total number of tradable Kodiak Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kodiak Sciences's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Kodiak Sciences shares in existence, roughly 70 shares are currently held short) or 0.1088% of the tradable shares (for every 100,000 tradable Kodiak Sciences shares, roughly 109 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kodiak Sciences.
Find out more about how you can short Kodiak Sciences stock.
We're not expecting Kodiak Sciences to pay a dividend over the next 12 months.
Over the last 12 months, Kodiak Sciences's shares have ranged in value from as little as $42.97 up to $171.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kodiak Sciences's is 1.381. This would suggest that Kodiak Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kodiak Sciences Inc. , a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.